Section Arrow
IRD.NASDAQ
- Opus Genetics Inc
Quotes are at least 15-min delayed:2026/08/04 11:52 EDT
Regular Hours
Last
 3.645
+0.005 (+0.14%)
Day High 
3.71 
Prev. Close
3.64 
1-M High
4.39 
Volume 
237.26K 
Bid
3.64
Ask
3.65
Day Low
3.605 
Open
3.67 
1-M Low
2.82 
Market Cap 
300.54M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 3.35 
20-SMA 3.5 
50-SMA 3.85 
52-W High 5.81 
52-W Low 1.04 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.31/-0.67
Enterprise Value
301.67M
Balance Sheet
Book Value Per Share
-0.56
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
14.20M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ENSCEnsysce Biosciences0.395+0.1149+41.02%-- 
VTGNVistagen Therapeutics, Inc.0.31185+0.06685+27.29%-- 
IBRXImmunityBio6.835-0.315-4.41%-- 
RXRXRecursion Pharmaceuticals3.335+0.155+4.87%-- 
GERNGeron Corp1.35+0.07+5.47%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.